Literature DB >> 22669437

[Botulinum toxin type A for preventive treatment of chronic migraines].

H Göbel1, A Heinze.   

Abstract

The use of botulinum toxin type A for chronic migraines was studied systematically in the PREEMPT trials program. Superiority to placebo treatment was established. Thus, for the first time a prophylactic drug against chronic migraines is available that is both effective and well tolerated. Botox® was licensed in England for the prophylaxis of headaches in adults with chronic migraines (headaches on at least 15 days per month of which at least 8 days are with migraines) in 2010.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22669437     DOI： 10.1007/s00106-012-2496-z

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


  15 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Authors:  H C Diener; D W Dodick; S K Aurora; C C Turkel; R E DeGryse; R B Lipton; S D Silberstein; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 3.  Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

Authors:  K R Aoki
Journal:  Neurotoxicology       Date:  2005-07-05       Impact factor: 4.294

4.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

5.  OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Authors:  David W Dodick; Catherine C Turkel; Ronald E DeGryse; Sheena K Aurora; Stephen D Silberstein; Richard B Lipton; Hans-Christoph Diener; Mitchell F Brin
Journal:  Headache       Date:  2010-05-07       Impact factor: 5.887

6.  Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.

Authors:  S D Silberstein; H Göbel; R Jensen; A H Elkind; R Degryse; J M C M Walcott; C Turkel
Journal:  Cephalalgia       Date:  2006-07       Impact factor: 6.292

7.  Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.

Authors:  W J Binder; M F Brin; A Blitzer; L D Schoenrock; J M Pogoda
Journal:  Otolaryngol Head Neck Surg       Date:  2000-12       Impact factor: 3.497

8.  Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.

Authors:  Susanne Petri; Thomas Tölle; Andreas Straube; Volker Pfaffenrath; Ulrich Stefenelli; Andres Ceballos-Baumann
Journal:  Eur Neurol       Date:  2009-07-20       Impact factor: 1.710

9.  Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Authors:  Sheena K Aurora; Marek Gawel; Jan L Brandes; Suriani Pokta; Amanda M Vandenburgh
Journal:  Headache       Date:  2007-04       Impact factor: 5.887

10.  Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.

Authors:  Adam J Shuhendler; Soyoung Lee; Michelle Siu; Stephanie Ondovcik; Kyla Lam; Awatif Alabdullatif; Xiaochu Zhang; Márcio Machado; Thomas R Einarson
Journal:  Pharmacotherapy       Date:  2009-07       Impact factor: 4.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.